- NBRVF Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
-
ETFs
- Insider
- Institutional
- Shorts
-
S-3 Filing
Nabriva Therapeutics (NBRVF) S-3Shelf registration
Filed: 16 Mar 18, 12:00am
CALCULATION OF CONSOLIDATED RATIOS OF EARNINGS TO FIXED CHARGES AND
CONSOLIDATED RATIOS OF EARNINGS TO COMBINED FIXED CHARGES AND PREFERRED SHARE DIVIDENDS
(dollars in thousands)
|
| 12/31/2013 |
| 12/31/2014 |
| 12/31/2015 |
| 12/31/2016 |
| 12/31/2017 |
| |||||
Fixed Charges: |
|
|
|
|
|
|
|
|
|
|
| |||||
Interest expense |
| $ | 1,647 |
| $ | 2,350 |
| $ | 22,026 |
| $ | 75 |
| $ | 2 |
|
Interest expense on portion of rent expense representative of interest |
| 282 |
| 286 |
| 287 |
| 421 |
| 421 |
| |||||
Total Fixed Charges |
| $ | 1,929 |
| $ | 2,636 |
| $ | 22,313 |
| $ | 496 |
| $ | 423 |
|
Earnings (loss): |
|
|
|
|
|
|
|
|
|
|
| |||||
Net Income (loss) from continuing operations |
| $ | 17,065 |
| $ | (14,222 | ) | $ | (46,964 | ) | $ | (54,890 | ) | $ | (74,356 | ) |
Fixed charges per above |
| 1,929 |
| 2,636 |
| 22,313 |
| 496 |
| 423 |
| |||||
Total earnings (loss) |
| 18,994 |
| (11,586 | ) | (24,651 | ) | (54,394 | ) | (73,933 | ) | |||||
Ratio of earnings to fixed charges |
| $ | 8.85 |
| $ | N/A |
| $ | N/A |
| $ | N/A |
| $ | N/A |
|
Deficiency of earnings available to cover fixed charges |
| $ | 17,065 |
| $ | (14,222 | ) | (46,964 | ) | (54,890 | ) | (74,356 | ) | |||
Preferred share dividend requirements |
| $ | — |
| $ | — |
| $ | 1,723 |
| $ | — |
| $ | — |
|
Total combined fixed charges and preferred share dividends |
| $ | 1,929 |
| $ | 2,636 |
| $ | 24,035 |
| $ | 496 |
| $ | 423 |
|
Ratios of earnings to combined fixed charges and preferred share dividends |
| 8.85 |
| N/A |
| N/A |
| N/A |
| N/A |
| |||||
Deficiency of earnings available to cover fixed charges and preferred share dividend requirements |
| $ | 17,065 |
| $ | (14,222 | ) | $ | (48,687 | ) | $ | (54,890 | ) | $ | (74,356 | ) |